These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37549505)

  • 41. Pharmacokinetics and Tolerability of a Novel 17β-Estradiol and Progesterone Intravaginal Ring in Sheep.
    Weiss H; Martell B; Constantine GD; Davis SM; Vidal JD; Mayer PR; Doorbar M; Friend DR
    J Pharm Sci; 2019 Aug; 108(8):2677-2684. PubMed ID: 30959058
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
    AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 3D printed clotrimazole intravaginal ring for the treatment of recurrent vaginal candidiasis.
    Tiboni M; Campana R; Frangipani E; Casettari L
    Int J Pharm; 2021 Mar; 596():120290. PubMed ID: 33524521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An update on multipurpose prevention technologies for the prevention of HIV transmission and pregnancy.
    Friend DR
    Expert Opin Drug Deliv; 2016; 13(4):533-45. PubMed ID: 26742698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.
    Thurman AR; Ravel J; Gajer P; Marzinke MA; Ouattara LA; Jacot T; Peet MM; Clark MR; Doncel GF
    Front Cell Infect Microbiol; 2022; 12():799501. PubMed ID: 35350436
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of an intravaginal ring delivering simultaneously anastrozole and levonorgestrel: a pharmacokinetic perspective.
    Nave R
    Drug Deliv; 2019 Dec; 26(1):586-594. PubMed ID: 31174438
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.
    Rosen RK; van den Berg JJ; Vargas SE; Senocak N; Shaw JG; Buckheit RW; Smith KA; Guthrie KM
    Contraception; 2015 Dec; 92(6):596-601. PubMed ID: 26276246
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
    Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF
    PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures.
    Srinivasan P; Moss JA; Gunawardana M; Churchman SA; Yang F; Dinh CT; Mitchell JM; Zhang J; Fanter R; Miller CS; Butkyavichene I; McNicholl JM; Smith TJ; Baum MM; Smith JM
    PLoS One; 2016; 11(6):e0157061. PubMed ID: 27275923
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.
    Keller MJ; Wood L; Billingsley JM; Ray LL; Goymer J; Sinclair S; McGinn AP; Marzinke MA; Frank B; Srinivasan S; Liu C; Atrio JM; Espinoza L; Mugo N; Spiegel HML; Anderson PL; Fredricks DN; Hendrix CW; Marrazzo J; Bosinger SE; Herold BC
    Lancet HIV; 2019 Aug; 6(8):e498-e508. PubMed ID: 31320290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: Development of dual-protection technologies.
    Friend DR; Doncel GF
    Antiviral Res; 2010 Dec; 88 Suppl 1():S47-54. PubMed ID: 21109068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The ring plus project: safety and acceptability of vaginal rings that protect women from unintended pregnancy.
    Schurmans C; De Baetselier I; Kestelyn E; Jespers V; Delvaux T; Agaba SK; van Loen H; Menten J; van de Wijgert J; Crucitti T;
    BMC Public Health; 2015 Apr; 15():348. PubMed ID: 25880636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration.
    Ouattara LA; Thurman AR; Jacot TA; Cottrell M; Sykes C; Blake K; Fang X; Ju S; Vann NC; Schwartz J; Doncel GF
    J Acquir Immune Defic Syndr; 2022 Jan; 89(1):87-97. PubMed ID: 34878438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-acting biodegradable implant for sustained delivery of antiretrovirals (ARVs) and hormones.
    Li L; Gatto GJ; Brand RM; Krovi SA; Cottrell ML; Norton C; van der Straten A; Johnson LM
    J Control Release; 2021 Dec; 340():188-199. PubMed ID: 34678316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repeated administration of high-dose depot medroxyprogesterone acetate does not alter SHIV
    Srinivasan P; Zhang J; Dinh CT; Teller RS; McNicholl JM; Kiser PF; Herold BC; Smith JM
    J Med Primatol; 2017 Aug; 46(4):129-136. PubMed ID: 28748662
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention.
    van der Straten A; Agot K; Ahmed K; Weinrib R; Browne EN; Manenzhe K; Owino F; Schwartz J; Minnis A;
    J Int AIDS Soc; 2018 Mar; 21(3):e25094. PubMed ID: 29600595
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention.
    Krovi SA; Johnson LM; Luecke E; Achilles SL; van der Straten A
    Adv Drug Deliv Rev; 2021 Sep; 176():113849. PubMed ID: 34186143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. pH-triggered polymeric nanoparticles in gel for preventing vaginal transmission of HIV and unintended pregnancy.
    Fernandes T; Patel V; Aranha C; Velhal S; Momin M; Mulkutkar M; Sawarkar S
    Eur J Pharm Biopharm; 2023 Oct; 191():219-234. PubMed ID: 37669727
    [TBL] [Abstract][Full Text] [Related]  

  • 59. End-Users' Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa.
    Weinrib R; Minnis A; Agot K; Ahmed K; Owino F; Manenzhe K; Cheng H; van der Straten A
    AIDS Behav; 2018 Jan; 22(1):133-145. PubMed ID: 29052018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling.
    Kinvig H; Cottura N; Lloyd A; Frivold C; Mistilis J; Jarrahian C; Siccardi M
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):855-868. PubMed ID: 36178586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.